No Prescription |
 |
 | ||
|
CAPEGARD GENERIC CAPECITABINE |
|
| ||
No Prescription » Prescription Drugs 3 » CAPEGARD GENERIC CAPECITABINE Your doctor has prescribed the drug bleomycin to help treat your illness. The drug is given by injection into a large muscle a vein or just under the skin. The drug also can be placed through a chest tube into the space surrounding the lungs. Occasionally small test doses are given to check your reaction before the remainder of the drug is administered.This medication is used to treat: lymphomas squamous cell carcinomas testicular carcinomas malignant pleural effusions This medication is sometimes prescribed for other uses; ask your doctor or pharmacist for more information.Bleomycin is an antibiotic that is used only for its cancer-fighting effects; it slows or stops the growth of cancer cells in your body. The length of treatment depends on the types of drugs you are taking how well your body responds to them and the type of cancer you have. Buy CAPEGARD GENERIC CAPECITABINE and other Prescription Drugs 3 products online at Medstore. 4802
About CAPEGARD GENERIC CAPECITABINE: Product Type: Prescription Drugs 3 CAPEGARD ( GENERIC CAPECITABINE ) CAPEGARD (GENERIC CAPECITABINE) GENERIC CAPECITABINE 500MG 50 Tablets GENERIC CAPECITABINE CAPEGARD
View more Prescription Drugs 3 No Prescription: NEW YORK, Oct. 5, 2011 /PRNewswire via COMTEX/ -- Reportlinker.com announces that a new market research report is available in its catalogue: European Pharmaceutical Market: Strategic Assessments of Leading Suppliers http://www.reportlinker.com/p0651431/European-Pharmaceutical-Market-Strategic-Assessments-of-Leading-Suppliers.html #utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication This report provides industry executives with strategically significant competitor information and analysis of the leading players in the European pharmaceutical market. The report provides a worldwide strategic overview of the pharmaceutical market, including: Sales forecast for major product segments: ethical, OTC, generics. Sales forecast for major drug categories: cardiovascular, gastrointestinal, antibiotic, CNS, respiratory, musculoskeletal, hormonal/genitourinary, dermatological, oncological, ophthalmic, and others. In addition, the report reviews major regulatory, technological, economic, demographic, and social trends with potentially significant impact on the market during the next five years, including discussion of such key issues as pricing, industry consolidation, market globalization, growing R&D cost, generics, as well as advances in genomics, proteomics, drug screening, tissue engineering, bioinformatics, and other technologies. The companies analyzed in this report include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis and Wyeth.
| ||
